Abstract:BackgroundThe use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder.MethodsThe reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds. The molecular docking study were carried out using autodock tool against peroxisome proliferator activated receptor alpha. The in vivo lipid profile were assayed using conventional methods. The kidney and liver function test were carried out to assess the effect of the derivatives on the organs. The LD50 of the most active derivatives were determined using mice.ResultsThe targeted compounds were successfully synthesized in excellent yields and characterized using spectroscopic techniques. The results of the molecular docking experiment showed that they were good stimulant of peroxisome proliferator activated receptor alpha. Compound 9f showed activity at Ki of 2.8 nM and binding energy of 12.6 kcal/mol. All the compounds tested reduced triglyceride, total cholesterol, low density lipoprotein cholesterol and very low density lipoprotein cholesterol level in the mice model. Some of the reported compounds also increased high density lipoprotein cholesterol level in the mice. The compounds did not have appreciable effect on the kidney and liver of the mice used. The LD50 showed that the novel compounds have improved toxicity profile.ConclusionThe synthesis of fifteen new derivatives of carboxamides bearing phenoxazinone and sulphonamide were successful. The compounds possessed comparable activity to gemfibrozil. The reported compounds had better toxicity profile than gemfibrozil and could serve as a replacement for the statins and fibrate class of lipid agents.

Structure-based Design, Synthesis, PPAR-γ Activation, and Molecular Docking of N-substituted Phthalimides

Design, Synthesis and Evaluation of PPAR Gamma Binding Activity of 2-Thioxo-4-thiazolidinone Derivatives

Design, Synthesis and Computational Insight of Isolated and Thiophene fused 2H‐Pyran‐2‐ones as PPAR‐γ Agonist

Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies

Exploring Dual Agonists for PPARα/γ Receptors Using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

Design, Synthesis, and Evaluation of Novel L-Phenylglycine Derivatives As Potential PPARγ Lead Compounds

Tryptophan-Containing Dipeptide Derivatives As Potent Ppar Gamma Antagonists: Design, Synthesis, Biological Evaluation, And Molecular Modeling

Virtual identification of novel peroxisome proliferator-activated receptor (PPAR) α/δ dual antagonist by 3D-QSAR, molecule docking and molecule dynamics simulation.

Synthesis and Identification of [1,2,4]thiadiazole Derivatives As A New Series of Potent and Orally Active Dual Agonists of Peroxisome Proliferator-Activated Receptors Alpha and Delta

Scaffold-based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors.

Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.

Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety

Design, Synthesis and PPAR Activities of 5-Arylmethylene and 5-Heteroaromatic Methylene Thiazolidine-2,4-diones

Structure-based De Novo Design, Synthesis, and Biological Evaluation of the Indole-Based PPARγ Ligands (I)

Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.

Raloxifene-driven benzothiophene derivatives: Discovery, structural refinement, and biological evaluation as potent PPARγ modulators based on drug repurposing

Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones As Potential PPARγ Partial Agonists for Preparation of Antidiabetic Agents

Synthesis of a 5-((Aryloxy)methyl)-3-(4-(trifluoromethyl)phenyl)[1,2,4]thiadiazole Derivative: A Promising PPARα,δ Agonist

Design, molecular docking and dynamics simulations of PPARs pan agonists

Design and Synthesis of Thiazolidinedione Derivates As Selective Ppar Gamma Modulators